Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Blokhin's Russian Cancer Research Center
Blokhin's Russian Cancer Research Center
Blokhin's Russian Cancer Research Center
University Health Network, Toronto
Meyer Children's Hospital IRCCS
Celon Pharma SA
Henan Cancer Hospital
Henan Cancer Hospital
Grupo Espanol de Investigacion en Sarcomas
Sun Yat-sen University
Sun Yat-sen University
Salarius Pharmaceuticals, LLC
Base Therapeutics (Shanghai) Co., Ltd.
Xiangya Hospital of Central South University
Centre Leon Berard
HRYZ Biotech Co.
Tracon Pharmaceuticals Inc.
Centre Leon Berard
Instituto do Cancer do Estado de São Paulo
Sun Yat-sen University
Sun Yat-sen University
Kineta Inc.
Shanghai Yunying Medical Technology
Shanghai Yunying Medical Technology
Sun Yat-sen University
Sun Yat-sen University
Sun Yat-sen University
Sun Yat-sen University
Grupo Espanol de Investigacion en Sarcomas
Grupo Espanol de Investigacion en Sarcomas
Grupo Espanol de Investigacion en Sarcomas
Institut Bergonié
Ludwig-Maximilians - University of Munich
Henan Cancer Hospital
Genzada Pharmaceuticals USA, Inc.
Peking University Cancer Hospital & Institute
Ascentage Pharma Group Inc.
Ruijin Hospital
ImmVira Pharma Co. Ltd
Istanbul Medeniyet University
Sun Yat-sen University
Maria Sklodowska-Curie National Research Institute of Oncology
Rigshospitalet, Denmark
Yonsei University
Fudan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Institut Bergonié
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
The Netherlands Cancer Institute
NHS Greater Glasgow and Clyde